HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $76 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for SpringWorks Therapeutics, maintaining a price target of $76. Analyst Robert Burns continues to show confidence in the company's potential.
August 28, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for SpringWorks Therapeutics, maintaining a price target of $76. This indicates continued confidence in the company's growth potential.
The reiteration of a Buy rating and maintenance of a $76 price target by HC Wainwright & Co. suggests strong confidence in SpringWorks Therapeutics' future performance. This is likely to positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100